215 related articles for article (PubMed ID: 37246089)
1. The Management of Relapsed or Refractory Waldenström's Macroglobulinemia.
García-Sanz R; Tedeschi A
Hematol Oncol Clin North Am; 2023 Aug; 37(4):727-749. PubMed ID: 37246089
[TBL] [Abstract][Full Text] [Related]
2. Treatment of relapsed and refractory Waldenstrom Macroglobulinemia.
Amaador K; Kersten MJ; Minnema MC; Vos JMI
Leuk Lymphoma; 2023 Jan; 64(1):30-41. PubMed ID: 36282673
[TBL] [Abstract][Full Text] [Related]
3. Novel agents in the treatment of Waldenström's macroglobulinemia.
Treon SP; Hatjiharissi E; Leleu X; Moreau AS; Roccaro A; Hunter ZR; Soumerai JD; Ciccarelli B; Xu L; Sacco A; Ngo HT; Jia X; Yang C; Adamia S; Branagan AR; Ho AW; Santos DD; Tournilhac O; Manning RJ; Leduc R; O'Connor K; Nelson M; Patterson CJ; Ghobrial I
Clin Lymphoma Myeloma; 2007 Aug; 7 Suppl 5():S199-206. PubMed ID: 17877845
[TBL] [Abstract][Full Text] [Related]
4. Waldenstrom's macroglobulinemia in the era of immunotherapy.
Vaxman I; Gertz M
Leuk Lymphoma; 2020 Jun; 61(6):1292-1304. PubMed ID: 31960730
[TBL] [Abstract][Full Text] [Related]
5. A safety profile of medications used to treat Waldenström's macroglobulinemia.
García-Sanz R; Jiménez C; González De La Calle V; Sarasquete ME
Expert Opin Drug Saf; 2018 Jun; 17(6):609-621. PubMed ID: 29768934
[TBL] [Abstract][Full Text] [Related]
6. A Canadian Perspective on the Treatment of Waldenström Macroglobulinemia.
Kaedbey R; Forward N; Sehn LH; Shafey M; Doucette S; Chen CI
Curr Oncol; 2022 Sep; 29(10):7122-7139. PubMed ID: 36290837
[TBL] [Abstract][Full Text] [Related]
7. [Therapeutic algorithm of Waldenström's macroglobulinemia or lymphoplasmacytic lymphoma in Japan].
Sekiguchi N
Rinsho Ketsueki; 2021; 62(8):1139-1148. PubMed ID: 34497201
[TBL] [Abstract][Full Text] [Related]
8. Managing complications secondary to Waldenström's macroglobulinemia.
Pessach I; Dimopoulos MA; Kastritis E
Expert Rev Hematol; 2021 Jul; 14(7):621-632. PubMed ID: 34170207
[No Abstract] [Full Text] [Related]
9. The Use of Bruton Tyrosine Kinase Inhibitors in Waldenström's Macroglobulinemia.
Khan AM
J Pers Med; 2022 Apr; 12(5):. PubMed ID: 35629099
[TBL] [Abstract][Full Text] [Related]
10. Current treatment options and investigational drugs for Waldenstrom's Macroglobulinemia.
Gavriatopoulou M; Terpos E; Kastritis E; Dimopoulos MA
Expert Opin Investig Drugs; 2017 Feb; 26(2):197-205. PubMed ID: 28043164
[TBL] [Abstract][Full Text] [Related]
11. Diagnostics in Waldenström's macroglobulinemia: a consensus statement of the European Consortium for Waldenström's Macroglobulinemia.
Dogliotti I; Jiménez C; Varettoni M; Talaulikar D; Bagratuni T; Ferrante M; Pérez J; Drandi D; Puig N; Gilestro M; García-Álvarez M; Owen R; Jurczak W; Tedeschi A; Leblond V; Kastritis E; Kersten MJ; D'Sa S; Kaščák M; Willenbacher W; Roccaro AM; Poulain S; Morel P; Kyriakou C; Fend F; Vos JMI; Dimopoulos MA; Buske C; Ferrero S; García-Sanz R
Leukemia; 2023 Feb; 37(2):388-395. PubMed ID: 36435884
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Owen RG; Treon SP; Al-Katib A; Fonseca R; Greipp PR; McMaster ML; Morra E; Pangalis GA; San Miguel JF; Branagan AR; Dimopoulos MA
Semin Oncol; 2003 Apr; 30(2):110-5. PubMed ID: 12720118
[TBL] [Abstract][Full Text] [Related]
13. Idelalisib in a patient with refractory Waldenström's macroglobulinemia complicated by anuric renal failure: a case report.
D'Aveni-Piney M; Divoux M; Busby-Venner H; Muller M; Broséus J; Feugier P
J Med Case Rep; 2018 Jun; 12(1):164. PubMed ID: 29890999
[TBL] [Abstract][Full Text] [Related]
14. What is new in the treatment of Waldenstrom macroglobulinemia?
Castillo JJ; Treon SP
Leukemia; 2019 Nov; 33(11):2555-2562. PubMed ID: 31591468
[TBL] [Abstract][Full Text] [Related]
15. Bortezomib as a treatment option in patients with Waldenström macroglobulinemia.
Dimopoulos MA; Chen C; Kastritis E; Gavriatopoulou M; Treon SP
Clin Lymphoma Myeloma Leuk; 2010 Apr; 10(2):110-7. PubMed ID: 20371443
[TBL] [Abstract][Full Text] [Related]
16. Pleural fluid MYD88 L265P mutation supporting diagnosis and decision to treat extramedullary Waldenstrom's macroglobulinemia: a case report.
Barnes M; Sharma P; Kumar V; Kaell A; LiPera W
J Med Case Rep; 2020 Jul; 14(1):98. PubMed ID: 32654665
[TBL] [Abstract][Full Text] [Related]
17. Waldenstrom's macroglobulinemia: Recent advances in biology and therapy.
Neparidze N; Dhodapkar MV
Clin Adv Hematol Oncol; 2009 Oct; 7(10):677-81, 687-90. PubMed ID: 20040909
[TBL] [Abstract][Full Text] [Related]
18. Report of consensus panel 2 from the 11th international workshop on Waldenström's macroglobulinemia on the management of relapsed or refractory WM patients.
D'Sa S; Matous JV; Advani R; Buske C; Castillo JJ; Gatt M; Kapoor P; Kersten MJ; Leblond V; Leiba M; Palomba ML; Paludo J; Qiu L; Sarosiek S; Shadman M; Talaulikar D; Tam CS; Tedeschi A; Thomas SK; Tohidi-Esfahani I; Trotman J; Varettoni M; Vos J; Garcia-Sanz R; San-Miguel J; Dimopoulos MA; Treon SP; Kastritis E
Semin Hematol; 2023 Mar; 60(2):80-89. PubMed ID: 37147252
[TBL] [Abstract][Full Text] [Related]
19. [Pathology, diagnostics, and treatment of Waldenström's macroglobulinaemia].
Holmström MO
Ugeskr Laeger; 2011 Oct; 173(41):2557-60. PubMed ID: 21985832
[TBL] [Abstract][Full Text] [Related]
20. Treatment recommendations in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia.
Gertz MA; Anagnostopoulos A; Anderson K; Branagan AR; Coleman M; Frankel SR; Giralt S; Levine T; Munshi N; Pestronk A; Rajkumar V; Treon SP
Semin Oncol; 2003 Apr; 30(2):121-6. PubMed ID: 12720120
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
